{"id":435473,"date":"2021-02-15T01:33:31","date_gmt":"2021-02-15T06:33:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=435473"},"modified":"2021-02-15T01:33:31","modified_gmt":"2021-02-15T06:33:31","slug":"nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/","title":{"rendered":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma"},"content":{"rendered":"<div class=\"mw_release\">\n<table style=\"border-collapse: collapse;margin-left:9pt;width:472.7pt;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Press Release<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE<sup>\u00ae<\/sup> In Agreement with Hikma<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>\u00a0<\/strong><\/p>\n<p> February 15, 2021 \u2013 release at 7:30 am CET <br \/>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion of ZERVIATE<sup>\u00ae<\/sup>, indicated for the treatment of ocular itching associated with allergic conjunctivitis. <\/p>\n<p> Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties.\u00a0 Hikma has strong and well-established U.S. commercial capabilities with medical sales representatives deployed across the country, serving the needs of general practitioners and family doctors.\u00a0 Hikma is a top-10 U.S. generic pharmaceutical company, developing, manufacturing and distributing a broad range of branded and non-branded generic medicines for customers and partners.\u00a0 Eyevance will continue to promote ZERVIATE to ophthalmology and optometry healthcare professionals in the U.S.\u00a0 Nicox and Eyevance have a license agreement for the commercialization of ZERVIATE in the U.S., where the product has been marketed since March 2020. <\/p>\n<p><strong>Gavin Spencer, Chief Business Officer of Nicox, said:<\/strong> \u201c<em>This creative deal by Eyevance, executed in good time for the crucial U.S. spring allergy season, expands their reach to include healthcare professionals outside eyecare, such as <\/em><em>allergists, general and family practitioners and pediatricians, who account for around 40% of the 1 million prescriptions for branded allergy products in the United States.<\/em><em> \u00a0The partnership may thus lead to an increase in sales and demonstrates Eyevance\u2019s strong commitment to maximizing the value of the ZERVIATE franchise in the United States.\u201d<\/em><\/p>\n<p> Under Nicox\u2019s licensing agreement with Eyevance, Nicox is eligible for up to $37.5 million in milestones payable on Eyevance achieving pre-defined sales targets, with $30 million of these milestones being triggered by annual sales of $100 million and above. \u00a0Nicox also receives tiered royalties<sup>1<\/sup> of 8% to 15% on net sales of ZERVIATE in the U.S., including those made as a result of promotion by HIKMA.\u00a0 Eyevance is responsible for all manufacturing, regulatory and commercialization activities for ZERVIATE in the United States, where ZERVIATE is protected by patents expected to remain in force until 2030 and 2032.<\/p>\n<p><strong>About Hikma<\/strong><\/p>\n<p> Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. \u00a0For more than 40 years, we&#8217;ve been creating high-quality medicines and making them accessible to the people who need them. \u00a0Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people&#8217;s lives. \u00a0We&#8217;re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. \u00a0Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. \u00a0We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. \u00a0For more information, please visit: <a href=\"http:\/\/www.hikma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.hikma.com<\/u><\/a>. <\/p>\n<p><strong>About ZERVIATE<\/strong><\/p>\n<p> ZERVIATE<sup>\u00ae<\/sup> (cetirizine ophthalmic solution), 0.24% is a novel formulation of cetirizine developed and approved for the first time for topical application in the eye for the treatment of ocular itching associated with allergic conjunctivitis.\u00a0 Cetirizine, the active ingredient in ZYRTEC<sup>\u00ae<\/sup>, is a second-generation antihistamine (H1 receptor antagonist) that binds competitively to histamine receptor sites.\u00a0 Cetirizine, in approved oral formulations, has a well-characterized systemic efficacy and safety profile with worldwide exposure resulting from 20 years of oral use.\u00a0 ZERVIATE was developed by Nicox as the first and only formulation of cetirizine for topical application in the eye. \u00a0For further details of ZERVIATE in the U.S., please go to <a href=\"http:\/\/www.myzerviate.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.myzerviate.com<\/u><\/a>. <\/p>\n<p> ZERVIATE is also licensed exclusively to Ocumension Therapeutics in the Chinese and South East Asian markets, Samil Pharmaceutical in South Korea and ITROM Pharmaceutical Group for Gulf and Arab Markets.<\/p>\n<p><strong>About Allergic Conjunctivitis<\/strong><\/p>\n<p> Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis.\u00a0 Conjunctivitis is an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids.\u00a0 It may affect one or both eyes.\u00a0 The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light.<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>About Nicox<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;text-align: justify;vertical-align: middle;vertical-align: top\">Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.\u00a0 Nicox\u2019s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.\u00a0 The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.\u00a0 Nicox generates revenue from VYZULTA<sup>\u00ae <\/sup>in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE\u2122 in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.\u00a0 <\/p>\n<p> Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma &amp; Bio and Next 150 indexes. <\/p>\n<p> For more information on Nicox, its products or pipeline, please visit: <a href=\"http:\/\/www.nicox.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.nicox.com<\/u><\/a><u>.<\/u><\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Analyst coverage<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"width:336.54px;vertical-align: top\">\u00a0<\/p>\n<p> Bryan, Garnier &amp; Co \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Victor Floc\u2019h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Paris, France<br \/>Cantor Fitzgerald\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Louise Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.<br \/>Edison Investment Research Pooya Hemami\u00a0\u00a0\u00a0\u00a0\u00a0 London, UK<br \/>H.C. Wainwright &amp; Co\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Yi Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.<br \/>Kepler Cheuvreux\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Damien Choplain Paris, France<\/p>\n<p><em>\u00a0<\/em><\/td>\n<td style=\"width:293.74px;vertical-align: middle;text-align: left;padding-left: 30.0px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <em>The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. \u00a0Nicox disavows any obligation to correct or to update the information contained in analyst reports.<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Contacts<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;vertical-align: top\">\n            <strong>Nicox<\/strong><br \/>\n            <br \/>Gavin Spencer<br \/>Executive Vice President, Chief Business Officer<br \/>&amp; Head of Corporate Development\u00a0 <br \/> T +33 (0)4 97 24 53 00<br \/><a href=\"mailto:communications@nicox.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>communications@nicox.com <\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"width:313.6px;vertical-align: top\">Investors &amp; Media<br \/>United States &amp; Europe <br \/> LifeSci Advisors, LLC <br \/>Mary-Ann Chang <br \/>T +44 7483 284 853<br \/><a href=\"mailto:mchang@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>mchang@lifesciadvisors.com<\/u><\/a><\/td>\n<td colspan=\"2\" style=\"width:316.67px;vertical-align: top\">Media<br \/>France<br \/>LifeSci Advisors, LLC<br \/>Sophie Baumont<br \/>M +33 (0)6 27 74 74 49 <br \/><a href=\"mailto:sophie@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>sophie@lifesciadvisors.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Forward-Looking Statements<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;text-align: justify;vertical-align: middle;vertical-align: top\">The information contained in this document may be modified without prior notice.\u00a0 This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.\u00a0 These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.\u00a0 Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.<\/p>\n<p> Risks factors which are likely to have a material effect on Nicox\u2019s business are presented in the 3<sup>rd<\/sup> chapter of the \u2018<em>Document d\u2019enregistrement universel, rapport financier annuel et rapport de gestion 2019<\/em>\u2019 filed with the French <em>Autorit\u00e9 des March\u00e9s Financiers<\/em> (AMF) on March 6, 2020 which are available on Nicox\u2019s website (<a href=\"http:\/\/www.nicox.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.nicox.com<\/u><\/a>) and (ii) as restated in the 4<sup>th<\/sup> chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox\u2019s website.<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:630.27px;vertical-align: top\">\n            <strong>Nicox S.A.<\/strong><br \/>\n            <br \/>Drakkar 2<br \/> B\u00e2t D, 2405 route des Dolines<br \/> CS 10313, Sophia Antipolis<br \/> 06560 Valbonne, France<br \/> T +33 (0)4 97 24 53 00<br \/> F +33 (0)4 97 24 53 99<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<hr \/>\n<p>\n        <sup>1<\/sup> Nicox committed to pay to Eyevance certain manufacturing costs, which will be deducted from these royalty payments, reducing the effective royalty initially to 5% net until such costs are paid<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/ab3b9f6c-2052-45d2-9d06-ae7dc2f4d1b8\" rel=\"noopener noreferrer\">EN_ZERVIATEEyevanceNonOphthaCoPromote_PR_20210215_F<\/a>\n        <\/li>\n<\/ul>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/630d6a08-7876-4bd0-ae84-23d621aa0bce\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Press Release Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma \u00a0 February 15, 2021 \u2013 release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion of ZERVIATE\u00ae, indicated for the treatment of ocular itching associated with allergic conjunctivitis. Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties.\u00a0 Hikma has strong and well-established U.S. commercial capabilities with medical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-435473","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Press Release Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma \u00a0 February 15, 2021 \u2013 release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion of ZERVIATE\u00ae, indicated for the treatment of ocular itching associated with allergic conjunctivitis. Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties.\u00a0 Hikma has strong and well-established U.S. commercial capabilities with medical &hellip; Continue reading &quot;Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-15T06:33:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma\",\"datePublished\":\"2021-02-15T06:33:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/\"},\"wordCount\":1288,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/\",\"name\":\"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==\",\"datePublished\":\"2021-02-15T06:33:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/","og_locale":"en_US","og_type":"article","og_title":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma - Market Newsdesk","og_description":"Press Release Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma \u00a0 February 15, 2021 \u2013 release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion of ZERVIATE\u00ae, indicated for the treatment of ocular itching associated with allergic conjunctivitis. Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties.\u00a0 Hikma has strong and well-established U.S. commercial capabilities with medical &hellip; Continue reading \"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-15T06:33:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma","datePublished":"2021-02-15T06:33:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/"},"wordCount":1288,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/","name":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==","datePublished":"2021-02-15T06:33:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ1NjQxNiM0MDA4NjgxMTAjMTAxMTIzMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-u-s-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=435473"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435473\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=435473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=435473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=435473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}